News details

 
Information title

JPMorgan steps in for Myriad Genetics review

Published on Wednesday 20 August 2008 - 16:26

Summary :
Fresh on the heels of its Phase III disaster with the Alzheimer's drug Flurizan, Myriad Genetics announced that it has brought in JPMorgan Chase to help it conduct a strategic review. The developer...
Read more

Information source

http://www.fiercebiotech.com/news/frontpage

Website description
Get the latest news on the biotech industry, biotech companies, FDA approval and clinical research. Sign up today for the biotech industry

Articles published on this website : 1 / 7 days - 4 / 30 days

Roche snaps up Memory Pharma for $50M Merck drug fails to improve Alzheimer's symptoms TorreyPines sells Alzheimer's rights to Eisai Medivation hands out big bonuses after Pfizer deal Fidelity invests $65 in EnVivo Pharma, takes over

Other articles published on other websites on the same day

Nursing center raising money for Alzheimer's cure Thursday http://www.ssnewstelegram.com/ Bees used for brain disease research http://www.livenews.com.au/ Research: National Gateway Security Survey 2008 Shows Interesting Changes In Threat Landscape http://press-releases.techwhack.com/ New research reports new method to protect brain cells from diseases like Alzheimer's http://www.physorg.com/ Man held in alleged scheme to cheat Alzheimer's patients http://www.ajc.com/ Alzheimer's Disease and Emerging Treatments Analyzed in Neurotech Insights http://www.prnewswire.com/ Putnam plans safety net for disabled http://wvgazette.com/ Alzheimer's team holds family dinner http://www.qconline.com/ Family steps in to help fight Alzheimer's http://http/ Protecting Brain Cells From Diseases Like Alzheimer's Using New Method http://www.sciencedaily.com/